Wednesday September 9, 8:04 am Eastern Time
Company Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Presents Exploratory Phase II Clinical Trial Data on Psoriasis
CARLSBAD, Calif., Sept. 9 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that it presented the results of an exploratory Phase II double-blind, placebo-controlled trial involving 84 patients with moderate to severe psoriasis. This nine arm clinical trial was designed to compare the company's potential T cell receptor (TCR) peptide therapeutic vaccine using different adjuvants and two different routes of administration in an effort to select the best formulation for future clinical development. The company believes the results suggest that the groups receiving intramuscular injections (IM) of TCR peptides along with Incomplete Freund's Adjuvant (IFA) showed improvement when compared to all other treatment groups. These other treatment groups included patients receiving IM injections of IFA alone, IM injections of the TCR peptides in DeTox(TM) adjuvant, intradermal injections of TCR peptides in saline or intradermal injections of saline alone. This data was presented at the 5th European Congress on Psoriasis/7th International Psoriasis Symposium on September 5 in Milan, Italy.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, with technologies in four core areas: HIV, autoimmune disease, gene therapy and cancer. The company is conducting clinical trials using immune-based therapies for HIV, rheumatoid arthritis, psoriasis, multiple sclerosis, colon cancer and brain cancer, and preclinical studies for melanoma and prostate cancers. The company is also developing gene therapy treatments for hemophilia and hepatitis using a proprietary gene delivery system.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including the uncertainty of successful completion of clinical trials, and those risks set forth from time to time in The Immune Response Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1997. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
SOURCE: The Immune Response Corporation
--------------------------------------------------------------------------------
More Quotes and News: Immune Response Corp (Nasdaq:IMNR - news)
Related News Categories: biotech, medical/pharmaceutical |
